• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Amneal Pharmaceuticals Inc (NQ: AMRX )

    8.390 -0.060 (-0.71%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,111,846
    Open 8.560
    Bid (Size) 8.200 (1)
    Ask (Size) 8.500 (1)
    Prev. Close 8.450
    Today's Range 8.270 - 8.580
    52wk Range 5.010 - 8.720
    Shares Outstanding 1,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
    JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris. 
    Via Benzinga
    Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire

    Performance

    YTD
    +40.30%
    +40.30%
    1 Month
    +9.67%
    +9.67%
    3 Month
    +22.48%
    +22.48%
    6 Month
    +55.95%
    +55.95%
    1 Year
    +35.10%
    +35.10%

    More News

    Read More
    Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Amneal Reports Second Quarter 2024 Financial Results
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal to Report Second Quarter 2024 Results on August 9, 2024
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
    From Kashiv BioSciences, LLC
    Via Business Wire
    Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Amneal Releases 2023 Environmental, Social and Governance Report
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    3 Stocks to Buy That Are Up 100% Over the Past 52 Weeks
    Via InvestorPlace
    Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
    From Amneal Pharmaceuticals, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.